Theravance Biopharma (TBPH) EBIT (2013 - 2026)
Theravance Biopharma (TBPH) reported EBIT of -$9.5 million for Q1 2026, up 34.3% year-over-year from -$7.1 million in Q1 2025, and down 147.39% quarter-over-quarter from $20.0 million in Q4 2025.
Theravance Biopharma (TBPH) EBIT (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBIT data on file, last reported at -$9.5 million in Q1 2026.
- EBIT for Q1 2026 came in at -$9.5 million, up 34.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 102.69% YoY), and the FY2025 annual result was $32.3 million, up 168.82% from the prior year.
- EBIT retreated to -$9.5 million in Q1 2026 per TBPH's latest filing, from $20.0 million in the prior quarter.
- Over five years, EBIT peaked at $20.0 million in Q4 2025 and troughed at -$38.5 million in Q1 2022.
- A 5-year average of -$12.2 million and a median of -$10.8 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT plunged 47.44% in 2024, then surged 317.52% in 2025.
- A 5-year view of EBIT shows it stood at -$17.4 million in 2022, then jumped by 64.2% to -$6.2 million in 2023, then tumbled by 47.44% to -$9.2 million in 2024, then surged by 317.52% to $20.0 million in 2025, then plunged by 147.39% to -$9.5 million in 2026.
- Business Quant data shows TBPH's EBIT at -$9.5 million in Q1 2026, $20.0 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -9.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.48 Mn |
| Dec 31, 2025 | 20.01 Mn |
| Sep 30, 2025 | -6.46 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -9.20 Mn |
| Sep 30, 2024 | -10.84 Mn |
| Jun 30, 2024 | -15.71 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -8.76 Mn |
| Jun 30, 2023 | -16.12 Mn |
| Mar 31, 2023 | -24.91 Mn |
| Dec 31, 2022 | -17.43 Mn |
| Sep 30, 2022 | -9.14 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -38.50 Mn |
| Dec 31, 2021 | -56.17 Mn |
| Sep 30, 2021 | -53.62 Mn |
| Jun 30, 2021 | -64.11 Mn |